Texaf: VISIT BY SECRETARY OF STATE ANTHONY BLINKEN TO SILIKIN VILLAGE
.AttachmentCommuniqué 220812EN_Blinken
Day: August 12, 2022
Logiq Reports Second Quarter 2022 Financial Results
Written by Customer Service on . Posted in Earnings Releases And Operating Results.
Company completed the spinoff of fintech & mobile solutions offering, GoLogiq, as an independent, publicly traded company
Logiq reports solid execution pursuing higher margin businesses with larger customer accounts on a consolidated and segment basis
Company focus is on direct-to-customer portal, which was launched in mid-April and is expected to produce significantly higher margins and revenuesNEW YORK, Aug. 12, 2022 (GLOBE NEWSWIRE) — Logiq, Inc. (OTCQX: LGIQ; NEO: LGIQ), a provider of digital consumer acquisition solutions, today announced its financial results for the second quarter of 2022 ended June 30, 2022, and its outlook for full-year 2022. Results consolidate GoLogiq, Inc. (OTC: GOLQ) financials, which was a Logiq majority-owned business segment until completion of the spinoff on July 27, 2022. Going forward,...
OneSavings Bank plc – Interim report for the six months ended 30 June 2022
Written by Customer Service on . Posted in Public Companies.
LEI: 213800WTQKOQI8ELD692
OneSavings Bank plc Interim report for the six months ended 30 June 2022
OneSavings Bank plc (OSB or the Group), the specialist lending and retail savings group, announces today its results for the six months ended 30 June 2022.
OSB is a wholly-owned subsidiary of OSB GROUP PLC (OSBG). OSBG has prepared its own interim report for the period ended 30 June 2022 which includes the results of OSB and its subsidiaries (the Group) and was published on 11 August 2022. OSB is also required to publish an interim report due to its listed debt.
Following the Combination with Charter Court Financial Services Group plc (CCFS) on 4 October 2019, this press release includes results on an underlying basis, in addition to the statutory basis, which Management believe provide a more consistent basis for comparing the Group’s results...
Nova Leap Health Corp. Posts Q2 2022 Results
Written by Customer Service on . Posted in Earnings Releases And Operating Results.
Revenue in USD
Revenue In USDAdjusted EBITDA & Operating Income (Loss) in USD $
Adjusted EBITDA & Operating Income (Loss) in USD $NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES
HALIFAX, Nova Scotia, Aug. 12, 2022 (GLOBE NEWSWIRE) — NOVA LEAP HEALTH CORP. (TSXV: NLH) (“Nova Leap” or “the Company”), a growing home health care organization, is pleased to announce the release of financial results for the quarter ended June 30, 2022. All amounts are in United States dollars unless otherwise specified.
Nova Leap Q2 2022 Financial Results
Financial results for the three and six months ended June 30, 2022 include the following:Q2 2022 revenues were the 2nd highest in the Company’s history;
Q2 2022 revenues of $6,986,758 increased by 37.4% relative to Q2 2021 revenues of $5,085,445...
D-Wave Quantum Inc. (NYSE: QBTS) Uniquely Positioned to Capture Significant TAM for Optimization Problems
Written by Customer Service on . Posted in Public Companies.
NEW YORK, Aug. 12, 2022 (GLOBE NEWSWIRE) — NetworkNewsAudio – D-Wave Quantum Inc. (NYSE: QBTS) announces the availability of a broadcast titled, “Investing in Quantum Computing: What Every Investor Needs to Know.”
To hear the AudioPressRelease, please visit: The NetworkNewsAudio News Podcast
To view the full editorial, please visit: https://nnw.fm/e1PTH
As the world’s only annealing quantum computing company, and with annealing quantum computing best suited for optimization problems, D-Wave Quantum Inc. (NYSE: QBTS) is uniquely positioned to capture a significant portion of the total addressable market (TAM) for combinatorial optimization problems.
In a world where 39% of enterprises have abandoned complex problems because of time and difficulty to solve limitations, D-Wave [delivers quantum-hybrid solutions to these complex problems...
Relief Therapeutics and Acer Therapeutics Announce that the European Commission Has Granted Orphan Drug Designation for ACER-001 in Maple Syrup Urine Disease
Written by Customer Service on . Posted in Public Companies.
Orphan designation provides potential for up to 10-year market exclusivity in the EU upon regulatory approval
GENEVA, Switzerland and NEWTON, Mass., Aug. 12, 2022 (GLOBE NEWSWIRE) — RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (Relief), and its collaboration partner, Acer Therapeutics Inc. (Nasdaq: ACER) (Acer), today announced that the European Commission has granted orphan medicinal product designation in the EU to ACER-001 (sodium phenylbutyrate) for the potential treatment of patients with Maple Syrup Urine Disease (MSUD). ACER-001 was granted orphan drug designation by the U.S. Food and Drug Administration (FDA) in the U.S. for MSUD in 2014.
“Orphan designation by the European Commission is another important milestone for the ACER-001 program that provides further validation of the important role we believe...
Milestone Scientific Schedules Second Quarter 2022 Financial Results and Business Update Conference Call
Written by Customer Service on . Posted in Public Companies.
ROSELAND, N.J., Aug. 12, 2022 (GLOBE NEWSWIRE) — Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments, that provide painless and precise injections, today announced that it will host a conference call at 8:30 AM Eastern Time on Tuesday, August 16, 2022, to discuss the company’s financial results for the second quarter ended June 30, 2022, as well as the company’s corporate progress and other developments.
The conference call will be available via telephone by dialing toll free 888-506-0062 for U.S. callers or +1 973-528-0011 for international callers and by entering the access code: 197590. A webcast of the call may be accessed at https://www.webcaster4.com/Webcast/Page/2306/46391or on the Investor Relations section of the Company’s website at https://www.milestonescientific.com/investors.
An...
BTCS Reports Q2 2022 Results
Written by Customer Service on . Posted in Public Companies.
Revenue for the first six months of 2022 rose to $1.1 million
Silver Spring, MD, Aug. 12, 2022 (GLOBE NEWSWIRE) — BTCS Inc. (Nasdaq: BTCS) (“BTCS” or the “Company”), a blockchain technology-focused company, announced results for the second quarter ending June 30, 2022.
Second Quarter 2022 Financial HighlightsRevenue increased 35% to $0.5 million from the prior-year quarter and decreased by 9% from the first quarter of 2022. The slight revenue decline from the first quarter of 2022 resulted from a decrease in Digital Asset prices throughout the quarter, partially offset by an increase in Digital Asset production as a result of our expanded blockchain infrastructure. Revenue for the first six months of 2022 rose to $1.1 million compared to $0.5 million for the same period in 2021, nearly reaching 2021 full-year revenue of $1.2 million.
Gross...
Integrated Financial Holdings, Inc. Second Quarter 2022 Financial Results
Written by Customer Service on . Posted in Earnings Releases And Operating Results.
RALEIGH, N.C., Aug. 12, 2022 (GLOBE NEWSWIRE) — Integrated Financial Holdings, Inc. (OTCQX: IFHI) (the “Company” or “IFHI”), the financial holding company for West Town Bank & Trust (“the Bank”), released its financial results for the three months and six months ended June 30, 2022. Highlights from the 2022 second quarter and year-to-date results include the following:Second quarter net income of $1.4 million or $0.63 per diluted share, compared to second quarter 2021 net income of $4.6 million or $2.07 per diluted share. Year-to-date net income was $5.0 million or $2.22 per diluted share compared to $8.5 million or $3.82 per diluted share in the prior year.
Net interest income of $5.1 million for the second quarter of 2022, compared to $4.1 million for the same period in 2021. For the year, net interest income was $10.4...
POINT Biopharma Reports Second Quarter 2022 Financial Results and Provides Business Highlights
Written by Customer Service on . Posted in Earnings Releases And Operating Results.
Additional data from the lead-in of PNT2002’s SPLASH trial on track for fall 2022 release
PNT6555, the lead of the pan-cancer PNT2004 fibroblast activation protein-alpha targeted program, enters Phase 1 clinical trial
INDIANAPOLIS, Aug. 12, 2022 (GLOBE NEWSWIRE) — POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development, and global access to life-changing radiopharmaceuticals, today announced financial results for the second quarter ended June 30, 2022 and provided an update on business highlights.
“We continue to execute across our pipeline and platform,” said Dr. Joe McCann, CEO of POINT Biopharma. “The Phase 3 SPLASH trial in pre-chemotherapy mCRPC began European randomization in the second quarter, and I look forward to the release of further data from the...
